Hardik Shah
2026.06.05 11:15

๐Ÿ“Š ๐ˆ๐๐•๐„๐’๐“๐Ž๐‘ ๐๐Ž๐“๐„: TD Cowen Raises Global ๐†๐‹๐-๐Ÿ Market Forecast to $๐Ÿ๐Ÿ“๐ŸŽ๐ by 2030 - $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US) $Novo Nordisk AS(NVO.US)

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค TD Cowen raises ๐†๐‹๐-๐Ÿ market forecast to $๐Ÿ๐Ÿ“๐ŸŽ๐ by ๐Ÿ๐ŸŽ๐Ÿ‘๐ŸŽ.

โžค Forecast increased from prior estimate of $๐Ÿ๐Ÿ‘๐Ÿ—๐.

โžค Expected patient population grows to ๐Ÿ“๐Ÿ—๐Œ, up from ๐Ÿ’๐Ÿ”๐Œ.

โžค Higher treatment volumes expected to offset ๐ฉ๐ซ๐ข๐œ๐ž ๐ซ๐ž๐๐ฎ๐œ๐ญ๐ข๐จ๐ง๐ฌ.

โžค Oral GLP-1 therapies projected to reach ๐Ÿ๐Ÿ’% of global sales.

โžค Forecast covers both ๐“๐ฒ๐ฉ๐ž ๐Ÿ ๐ƒ๐ข๐š๐›๐ž๐ญ๐ž๐ฌ and obesity treatments.

โžค Eli Lilly and Novo Nordisk expected to retain dominant ๐ฆ๐š๐ซ๐ค๐ž๐ญ ๐ฌ๐ก๐š๐ซ๐ž๐ฌ.

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

ยฉ 2026 Longbridge๏ฝœDisclaimer